Journal
CANCER MANAGEMENT AND RESEARCH
Volume 12, Issue -, Pages 3651-3659Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S250394
Keywords
borderline ovarian tumor; diagnosis; prognosis; molecular characterization
Categories
Funding
- National Natural Science Foundation of China [81602285, 81872126]
- Nanjing Medical Science and technique Development Foundation [JQX17009]
Ask authors/readers for more resources
Borderline ovarian tumors (BOTs) are a type of low malignant potential tumor that is typically associated with better outcomes than ovarian cancer. Indeed, its 10-year survival rate is as high as 95%. However, there is a small subset of patients who experience relapse and eventually die. It has been shown that the prognosis of BOTs was based on pathological diagnosis, the age at diagnosis, pre-operative carbohydrate antigen 125 level, invasive implants, and micropapillary patterns. Now the molecular-targeted therapy and molecular-genetic diagnosis have developed into a form of precision medicine. Recent studies on extensive molecular characterizations and molecular pathological mechanisms of BOTs have helped us understand the genomic landscapes of BOTs, and therefore BOTs could be reclassified into biologically and clinically more accurate and effective subtypes. The purpose of this review is to summarize current status for the diagnosis and treatment of BOTs and to describe the research progress on molecular pathologies, with a goal of providing a theoretical perspective for the diagnosis and treatment of BOTs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available